PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Dartmouth/Univ. of Exeter Study: Correcting myths about the flu vaccine

Correcting myths may not effectively promote immunization

2014-12-08
(Press-News.org) HANOVER, N.H. - December 8, 2014 - With health systems in the U.S., U.K., and around the world trying to increase vaccination levels, it is critical to understand how to address vaccine hesitancy and counter myths about vaccine safety. A new article in the journal "Vaccine" concludes, however, that correcting myths about vaccines may not be the most effective approach to promoting immunization among vaccine skeptics. The study, which was co-authored by Brendan Nyhan, an assistant professor of government at Dartmouth College, and Jason Reifler, a senior lecturer of politics at the University of Exeter, found that debunking the myth that the seasonal influenza vaccine can give you the flu actually reduced intent to vaccinate among people who are most concerned about vaccine side effects. (The journal article will be available on December 8 on Vaccine's site via doi:10.1016/j.vaccine.2014.11.017).

The study was conducted with a nationally representative sample of adults in the U.S. collected as part of the 2012 Cooperative Congressional Election Survey. Respondents were randomly assigned to one of three conditions: a control condition in which no additional information about the flu or flu vaccines; a danger condition that presented information about the health risks posed by the flu; and a correction condition that informed respondents that they cannot contract the flu from the flu shot or live virus nasal spray. Both interventions were adapted nearly verbatim from Centers for Disease Control and Prevention materials. The researchers then compared the beliefs and intended behaviors of respondents after exposure to these messages.

The following is an overview of the study's results:

More than four in ten Americans (43%) endorsed the myth that the flu vaccine can give you the flu, saying it is either "somewhat" or "very accurate."

Respondents who received corrective information that the flu vaccine cannot give you the flu were less likely to report believing in this misperception or to say that the flu vaccine is unsafe.

However, providing this corrective information also reduced the self-reported likelihood of getting a flu vaccine among respondents with high levels of concern about vaccine side effects. This information had no significant effect on intention to vaccinate among respondents with low concern about side effects.

Providing information about the dangers of the flu had no effect on respondent beliefs about vaccine safety or their self-reported intention to vaccinate.

"Our findings suggest that corrective information can successfully reduce false beliefs about vaccines. However, that corrective information may unfortunately cause people with fears about side effects to bring those other concerns to mind and thereby reduce their intention to vaccinate," said Nyhan. "We need to learn how to most effectively promote immunization. Directly correcting vaccine myths may not be the most effective approach."

The study's results are consistent with other findings by Nyhan and Reifler, which indicate that corrections of misperceptions about controversial issues may have unexpected or counterproductive results, including a previous study of the effects of correcting misperceptions about the measles, mumps, and rubella (MMR) vaccine. Previous study links: http://link.springer.com/article/10.1007%2Fs11109-010-9112-2 http://pediatrics.aappublications.org/content/early/2014/02/25/peds.2013-2365

INFORMATION:

The published paper "Does correcting myths about the flu vaccine work? An experimental evaluation of the effects of corrective information" by Brendan Nyhan and Jason Reifler will appear in Vaccine, which is published by Elsevier. Copies of the paper are available to credentialed journalists upon request; please contact Amy Olson at amy.d.olson@dartmouth.edu or 603-646-3274 or Elsevier's Newsroom at newsroom@elsevier.com or +31-20-4853564. About Vaccine Vaccine is the pre-eminent journal for those interested in vaccines and vaccination. It is the official journal of The Edward Jenner Society, The International Society for Vaccines and The Japanese Society for Vaccinology. www.elsevier.com/locate/vaccine The study's co-authors are available to comment. For more information, Brendan Nyhan can be contacted at brendan.j.nyhan@dartmouth.edu or on his cell phone at +1 (919) 452-6451. Jason Reifler can be reached at j.reifler@exter.ac.uk or on his cell phone at +44 (0)7831 152405.



ELSE PRESS RELEASES FROM THIS DATE:

Penn researchers announce latest results of investigational cellular therapy

2014-12-08
SAN FRANCISCO - The latest results of clinical trials of more than 125 patients testing an investigational personalized cellular therapy known as CTL019 will be presented by a University of Pennsylvania research team at the 56th American Society of Hematology Annual Meeting and Exposition. Highlights of the new trial results will include a response rate of more than 90 percent among pediatric acute lymphoblastic leukemia patients, and results from the first lymphoma trials testing the approach, including a 100 percent response rate among follicular lymphoma patients and ...

Narrow subset of cells is responsible for metastasis in multiple myeloma, study finds

2014-12-08
Although it is among the most highly metastatic of all cancers, multiple myeloma is driven to spread by only a subset of the myeloma cells within a patient's body, researchers at Dana-Farber Cancer Institute have found in a study presented at the annual meeting of the American Society of Hematology (ASH). The study suggests that attacking those subsets with targeted drugs may degrade the disease's ability to spread throughout the bone marrow of affected patients, the authors say. The discovery was made by developing a mouse model of the disease that enabled researchers ...

Oral inhibitor shows clinical activity in poor-prognosis AML

2014-12-08
An oral targeted drug has shown encouraging activity and tolerable side effects in patients with treatment-resistant or relapsed acute myelogenous leukemia (AML) - a poor-prognosis group with few options - report investigators from Dana-Farber Cancer Institute and M.D. Anderson Cancer Center.   Of 32 patients treated with the oral inhibitor ABT-199, five had eradication of their leukemia and several more had stable disease, according to Anthony Letai, MD, PhD, of Dana-Farber, senior author of the report.     The phase 2 multicenter trial was the first ...

Combination therapy shown as effective for higher-risk MDS/AML patients

Combination therapy shown as effective for higher-risk MDS/AML patients
2014-12-08
A phase two study that investigated the potential of the drugs azacitidine (AZA) and lenalidomide (LEN), demonstrated that the two therapies in combination may be an effective frontline treatment regimen for patients with higher-risk forms of myelodysplastic syndrome and acute myeloid leukemia. Myelodysplastic syndrome (MDS) is a type of cancer in which the bone marrow does not make enough healthy blood cells, resulting in abnormal (blast) cells in the blood and/or bone marrow. Higher-risk patients experience an unusually large percentage of blasts in their blood. Patients ...

New study identifies first gene associated with familial glioma

2014-12-07
HOUSTON - (Dec. 7, 2014) - An international consortium of researchers led by Baylor College of Medicine has identified for the first time a gene associated with familial glioma (brain tumors that appear in two or more members of the same family) providing new support that certain people may be genetically predisposed to the disease. "It is widely thought amongst the clinical community that there is no association between family history and development of glioma. Because we know very little about the contributing genetic factors, when cases occur in two or more family ...

Study shows improved survival in aggressive acute myeloid leukemia

Study shows improved survival in aggressive acute myeloid leukemia
2014-12-07
Patients who relapse in their battle with acute myeloid leukemia (AML) may benefit from a phase three study of therapies that combine an existing agent, cytarabine, with a newer compound, vosaroxin. The study, led by Farhad Ravandi, M.D, professor of medicine, department of leukemia at The University of Texas MD Anderson Cancer Center, demonstrated increased survival rates, particularly in AML patients over age 60. Ravandi's study results were presented today at the 56th Annual Meeting of the American Society of Hematology (ASH) annual conference in San Francisco and ...

Young adults with ALL benefit from therapies developed for children

2014-12-07
Results from a large, prospective clinical trial add to mounting evidence that adolescent and young adult patients--aged 16 to 39 with acute lymphoblastic leukemia (ALL)--tend to fare better when treated with high-intensity pediatric protocols than previous patients who were treated with standard adult regimens. The intergroup trial, presented at the 56th annual meeting of the American Society of Hematology, enrolled 296 adolescent and young adult patients with ALL. All participants were treated by adult hematologists-oncologists on a pediatric protocol, including four ...

Stem cell transplant without radiation or chemotherapy pre-treatment shows promise

Stem cell transplant without radiation or chemotherapy pre-treatment shows promise
2014-12-07
SAN FRANCISCO (DECEMBER 7, 2014) - Researchers at Dana-Farber/Boston Children's Cancer and Blood Disorders Center report promising outcomes from a clinical trial with patients with a rare form of bone marrow failure who received a hematopoietic stem cell transplant (HSCT) after pre-treatment with immunosuppressive drugs only. This is the first trial reporting successful transplant in dyskeratosis congenita (DC) patients without the use of any radiation or conventional cytotoxic chemotherapy beforehand. The trial's data were presented by study authors Leslie Lehmann, MD, ...

Novel combinations yield promising results for leukemia patients with poor prognoses

2014-12-07
(SAN FRANCISCO, DECEMBER 7, 2014) - Recognizing that leukemia cannot be conquered with a "one-size-fits-all" approach, researchers are pursuing novel targeted therapies and combinations of existing treatment regimens with new agents for patient populations with historically poor prognoses, according to data presented today during the 56th American Society of Hematology (ASH) Annual Meeting and Exposition. In recent years, outcomes for patients with leukemia have steadily improved with the emergence of numerous therapies that target specific genetic drivers of disease, ...

Study shows new kind of targeted drug has promise for leukemia patients

2014-12-07
SAN FRANCISCO, CA, December 7, 2014--A new type of cancer therapy that targets an oncometabolite produced dramatic results in patients with advanced leukemia in an early-phase clinical trial. The study, led by Eytan M. Stein, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, was presented today at the 56th Annual Meeting of the American Society of Hematology. Approximately 15 percent of acute myeloid leukemia patients have a mutated form of the IDH2 gene. IDH2 normally makes a protein that plays a critical role in cell metabolism. However, when the gene ...

LAST 30 PRESS RELEASES:

iRECODE: A new computational method that brings clarity to single-cell analysis

New NUS-MOH study: Singapore’s healthcare sector carbon emissions 18% lower than expected, a milestone in the city-state’s net zero journey

QUT scientists create material to turn waste heat into clean power

Major new report sets out how to tackle the ‘profound and lasting impact’ of COVID-19 on cardiovascular health

Cosmic crime scene: White dwarf found devouring Pluto-like icy world

Major report tackles Covid’s cardiovascular crisis head-on

A third of licensed GPs in England not working in NHS general practice

ChatGPT “thought on the fly” when put through Ancient Greek maths puzzle

Engineers uncover why tiny particles form clusters in turbulent air

GLP-1RA drugs dramatically reduce death and cardiovascular risk in psoriasis patients

Psoriasis linked to increased risk of vision-threatening eye disease, study finds

Reprogramming obesity: New drug from Italian biotech aims to treat the underlying causes of obesity

Type 2 diabetes may accelerate development of multiple chronic diseases, particularly in the early stages, UK Biobank study suggests

Resistance training may improve nerve health, slow aging process, study shows

Common and inexpensive medicine halves the risk of recurrence in patients with colorectal cancer

SwRI-built instruments to monitor, provide advanced warning of space weather events

Breakthrough advances sodium-based battery design

New targeted radiation therapy shows near-complete response in rare sarcoma patients

Does physical frailty contribute to dementia?

Soccer headers and brain health: Study finds changes within folds of the brain

Decoding plants’ language of light

UNC Greensboro study finds ticks carrying Lyme disease moving into western NC

New implant restores blood pressure balance after spinal cord injury

New York City's medical specialist advantage may be an illusion, new NYU Tandon research shows

Could a local anesthetic that doesn’t impair motor function be within reach?

1 in 8 Italian cetacean strandings show evidence of fishery interactions, with bottlenose and striped dolphins most commonly affected, according to analysis across four decades of data and more than 5

In the wild, chimpanzees likely ingest the equivalent of several alcoholic drinks every day

Warming of 2°C intensifies Arctic carbon sink but weakens Alpine sink, study finds

Bronze and Iron Age cultures in the Middle East were committed to wine production

Indian adolescents are mostly starting their periods at an earlier age than 25 years ago

[Press-News.org] Dartmouth/Univ. of Exeter Study: Correcting myths about the flu vaccine
Correcting myths may not effectively promote immunization